Bell Potter downgrades Sigma Healthcare stock to Hold at AUD 3.00

Published on 10/20/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sigma reports AUD 10.8 billion fiscal 2026 revenue, up 81 percent. Sigma Healthcare stock costs EUR 1.77 on October 20, 2026, unchanged on ASX.

Bell Potter changes its rating

Bell Potter moved Sigma Healthcare from Buy to Hold on October 20, 2026, while keeping its AUD 3.00 target.
Fiscal 2026 revenue reached AUD 10.8 billion, up 81 percent from fiscal 2025.
Sigma Healthcare stock costs EUR 1.77 at Lang & Schwarz on October 20, 2026 at 9:39 p.m. CEST.
The annual general meeting is scheduled for October 21, 2026.

Sigma, AU000000SIG5, Illustration mit AI erstellt.

Sigma Healthcare (AU000000SIG5) faces a fresh rating shift as Bell Potter moved the stock from Buy to Hold on October 20, 2026, while leaving its price target at AUD 3.00, according to The Motley Fool Australia. The target stood 6.01 percent above the ASX close of AUD 2.83 on October 20, 2026, while Sigma stock was trading at EUR 1.77 at Lang & Schwarz on October 20, 2026 at 9:39 p.m. CEST.

Bell Potter keeps AUD 3.00 target

The rating change leaves the target unchanged but lowers the broker's stance after a period of share price strength. The Motley Fool Australia reported that Bell Potter expects an update at Sigma's annual general meeting, with like-for-like network sales growth a key operating measure.

The same report cited Bell Potter's expectation of 12 percent to 13 percent network like-for-like sales growth for fiscal 2027. It also said the broker viewed new GLP-1 medicines as a potential source of pharmacy demand, while describing the shares as expensive relative to the growth outlook.

Revenue rose to AUD 10.8 billion

Sigma's fiscal 2026 revenue reached AUD 10.8 billion, up 81 percent from fiscal 2025, while net income rose 34 percent to AUD 709.2 million, according to Simply Wall St. Fiscal 2026 earnings per share increased to AUD 0.062 from AUD 0.051 in fiscal 2025, although profit margin declined to 6.5 percent from 8.8 percent.

The figures put the rating change in a mixed operating setting: revenue expanded sharply, but the lower margin points to higher expenses. Sigma operates a pharmacy franchise and pharmaceutical wholesale network supporting almost 900 franchised pharmacies across Amcal, Chemist Warehouse and Discount Drug Stores, according to the company's website.

Price stays below the yearly high

Sigma's ASX quote stood at AUD 2.83 at 4:11 p.m. AEDT on October 20, 2026, unchanged from the prior close. Its 52-week range was AUD 2.47 to AUD 3.20, and its market capitalization was AUD 32.3 billion, according to Simply Wall St. The stock therefore stood 11.56 percent below its 52-week high and 14.57 percent above its 52-week low.

AGM is scheduled for October 21

Sigma's annual general meeting is scheduled for October 21, 2026, with the event expected to provide a three-month trading update, according to The Motley Fool Australia. The company's fiscal 2026 results were last reported for the period ended June 30, 2026, and its trailing P/E ratio was 46.20, according to Simply Wall St.

What the rating change means

Bell Potter's unchanged AUD 3.00 target implies 6.01 percent upside from the ASX close, but the Hold rating places greater weight on valuation and the higher fiscal 2027 growth hurdle. The next concrete checkpoint is the October 21 AGM and its operating update.

Sigma stock in Germany

Sigma Healthcare stock was trading at EUR 1.77 at Lang & Schwarz on October 20, 2026 at 9:39 p.m. CEST. The German quote reflects the after-hours phase for investors in Germany.

The further course of trading is shown by the continuously updated real-time quote of Sigma Healthcare stock.